Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial

Keyphrases

• Interleukin-2 100%
• Multicenter Trial 100%
• Metastatic Renal Cell Carcinoma (mRCC) 100%
• Complete Remission 28%
• Median Survival 28%
• Phase II Trial 28%
• Survival Duration 28%
• Fever 14%
• Creatinine 14%
• Confidence Interval 14%
• Weight Loss 14%
• Acetaminophen 14%
• Response Rate 14%
• Eosinophilia 14%
• Rash 14%
• Follow-up Interval 14%
• Renal Cancer 14%
• Previously Untreated Patients 14%
• Treatment Course 14%
• Renal Disease 14%
• Duration of Therapy 14%
• Partial Remission 14%
• Rest Period 14%
• Toxic Death 14%
• Indomethacin 14%
• New Agents 14%
• Anorexia 14%
• Symptom Complex 14%
• Diphenhydramine 14%

Nursing and Health Professions

• Outpatient 100%
• Interleukin 2 100%
• Remission 42%
• Low Drug Dose 28%
• Confidence Interval 14%
• Treatment Duration 14%
• Creatinine 14%
• Immunotherapy 14%
• Tylenol 14%
• Anorexia 14%
• Indometacin 14%
• Benadryl 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Eosinophilia 14%
• Lymphocytosis 14%